Beginning in the first week of January 2025, in a big step forward towards giving my clients more than talk therapy, I will incorporate Ketamine-Assisted Psychotherapy (KAP) into my practice. I will do this in collaboration with Journey Clinical Inc., a healthcare company that specializes in providing evidence-based psychedelic-assisted psychotherapy treatments.

KAP can be a game changer for those clients who feel stuck in their therapy goals and feel that regular talk therapy, and even certain medications, doesn’t work for them enough to resolve their issues. It can bring about rapid therapeutic change, help clients with navigating and overcoming obstacles that cause them stress or impair their functioning.

My role in this arrangement will be limited to referring clients to Journey Clinical who will evaluate and determine their eligibility for KAP, as well as developing treatment plans. It will also be my responsibility to oversee dosing and reintegration sessions for clients. So, Journey Clinical will determine the eligibility of clients to benefit from the KAP, as well as prescribing the medicine and developing individualized treatment plans.

As an adjunct to talk therapy, KAP is used to afford the clients opportunities for self-exploration and to enhance therapeutic work. It can be administered in-person, remote, group or self-guided settings. It also facilitates the client’s ability to work through difficult experiences. Ketamine itself is considered safe to use but KAP may not be suitable for certain people with some medical and psychiatric conditions, including those with uncontrolled substance use disorders. Also, people must be 18 years old or above and be diagnosed with certain conditions to benefit from the treatment. Journey Clinical has reported that “87% of our KAP patients report improvement in their depression and anxiety clinical scores after 2 medical visits.”